Barinthus Biotherapeutics plc
BRNS
$0.73
$0.011.22%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 522,500.00% | -100.01% | |||
| Gross Profit | -522,500.00% | 100.01% | |||
| SG&A Expenses | -65.46% | 18.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -453.85% | 55.17% | |||
| Total Operating Expenses | -53.48% | 6.72% | |||
| Operating Income | 53.48% | -6.72% | |||
| Income Before Tax | 30.77% | -7.47% | |||
| Income Tax Expenses | -184.00% | -13.64% | |||
| Earnings from Continuing Operations | 31.03% | -7.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 150.00% | -80.00% | |||
| Net Income | 31.05% | -7.51% | |||
| EBIT | 53.48% | -6.72% | |||
| EBITDA | 51.28% | -7.32% | |||
| EPS Basic | 31.59% | -7.30% | |||
| Normalized Basic EPS | 52.93% | -5.71% | |||
| EPS Diluted | 31.25% | -6.86% | |||
| Normalized Diluted EPS | 52.93% | -5.71% | |||
| Average Basic Shares Outstanding | 0.79% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.79% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||